Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

Nature Biotechnology

Volumn 20, Issue 6, 2002, Pages 597-601

  Maynard, Jennifer A ^a,b   Maassen, Catharina B M ^b   Leppla, Stephen H ^c   Brasky, Kathleen ^d   Iverson, Brent L ^b   Georgiou, George ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; BIOTECHNOLOGY;

ANTHRAX TOXIN;

ANTIBODIES;

ANTHRAX TOXIN; ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BACILLUS ANTHRACIS; BINDING AFFINITY; CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION CONSTANT; HALF LIFE TIME; MACROPHAGE; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY AFFINITY; BINDING COMPETITION; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECT; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; MOUSE; PROTEIN BINDING; PROTEIN ENGINEERING;

AMINO ACID SEQUENCE; ANIMAL; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BINDING, COMPETITIVE; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULINS, KAPPA-CHAIN; MICE; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN ENGINEERING; RATS; RATS, INBRED F344; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, NON-P.H.S.; ANIMALS; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS;

EID: 0035984720     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0602-597     Document Type: Article

References (43)

1. The Sverdlosk anthrax outbreak of 1979
2. Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax
3. Anthrax vaccines: Past, present, and future
4. Anthrax
5. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States
6. The statistical analysis of truncated data: Application to the Sverdlovsk anthrax outbreak
7. Identification of the cellular receptor for anthrax
8. Anthrax toxin
9. Designing a polyvalent inhibitor of anthrax toxin
10. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies
11. Dominant-negative mutants of a toxin subunit: An approach to therapy of anthrax
12. A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin in vivo
13. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin
14. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs
15. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization
16. Passive immunity in prevention and treatment of infectious diseases
17. Antibodies for defense against biological attack
18. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncitial virus
19. In vitro correlate of immunity in a rabbit model of inhalational anthrax
20. Search for correlates of protective immunity conferred by anthrax vaccine
21. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores
22. Direct random mutagenesis of gene sized DNA fragments using polymerase chain reaction
23. Rapid evolution of a protein in vitro by DNA shuffling
24. Improved expression characteristics of single chain Fv fragments when fused downstream of the E. coli maltose binding protein or upstream of a single immunoglobulin constant domain
25. High affinity restricts the localization and tumor penetration of single-chain Fv antibodies
26. Humanization of an anti-p185/HER2 antibody for human cancer therapy
27. Tumor targeting of mono-, di-, and tetravalent anti-p185HER2 miniantibodies multimerized by self associating peptides
28. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3
29. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas
30. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterization of an engineered scFv fragment
31. Tailoring in vitro evolution for protein affinity or stability
32. Construction, binding properties, metabolism, and tumor-targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
33. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells
34. Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin
35. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin
36. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system
37. Escherichia coli skp chaperone coexpression improves solubility and phage display of single-chain antibody fragments
38. In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site
39. Measuring and increasing protein stability
40. Measuring the conformational stability of a protein
41. Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies
42. Preclinical pharmacokinetics, interspecies scaling, and tissue distriution of a humanized monoclonal antibody against vascular endothelial growth factor